Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis by Rueda Gotor, Javier et al.
Research Article
Relative Risk Chart Score for the Assessment of
the Cardiovascular Risk in Young Patients with
Ankylosing Spondylitis
Javier Rueda-Gotor ,1 Fernanda Genre ,1 Alfonso Corrales,1
Ricardo Blanco ,1 Patricia Fuentevilla,1 Virginia Portilla,1 Rosa Expósito,2
Cristina Mata Arnaiz,2 Trinitario Pina ,1 Carlos González-Juanatey,3
Luis Rodriguez-Rodriguez,4 andMiguel A. González-Gay 1
1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Division of Rheumatology,
Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
2Division of Rheumatology, Hospital Comarcal, Laredo, Cantabria, Spain
3Division of Cardiology, Hospital Lucus Augusti, Lugo, Spain
4Division of Rheumatology, Instituto de Investigación Sanitaria del Hospital Cĺınico San Carlos (IDISSC), Hospital Cĺınico San Carlos,
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Objective. To determine if the use of the relative risk (RR) chart score may help to identify young ankylosing spondylitis (AS)
patients at high risk of cardiovascular (CV) disease. Methods. 73 AS patients younger than 50 years were assessed. CV risk was
calculated according to the total cholesterol systematic coronary risk evaluation (TC-SCORE) and the RR chart score. C-reactive
protein (CRP) value at disease diagnosis and carotid ultrasound data were also analyzed. Results. Twenty (27.4%) patients exhibited
carotid plaques being classified into the category of very highCV risk. None of themwas found to have a high/very highTC-SCORE.
CRP > 3mg/L at disease diagnosis was associated with the presence of carotid plaques (odds ratio 5.66, 𝑝 = 0.03). Whereas only 5
(14.2%) of the 35 patients with RR = 1 had carotid plaques, 15 (39.5%) of 38 with RR > 1 showed plaques. A model that included the
performance of carotid US in patients with RR > 1 who had CRP > 3mg/L allowed us to identify 60% of very high risk patients, with
a specificity of 77.4%. Conclusions. RR chart score assessment may help to identify young AS patients at high risk of CV disease.
1. Introduction
Ankylosing spondylitis (AS) is a type of inflammatory arthri-
tis that causes low back pain in young individuals, starting
typically before the age of 45 [1]. This chronic inflammatory
disease is associated with an increased cardiovascular (CV)
mortality [2].
The 2016 European Society of Cardiology (ESC) guide-
lines on CV disease prevention recommend using the sys-
tematic coronary risk evaluation (SCORE), as predictive
model to estimate the individual’s absolute risk for fatal CV
event [3]. The SCORE includes the following variables: age,
sex, lipid levels, smoking, and blood pressure [3]. The age
is the variable with the greatest influence in this model
[3]. Unfortunately, the SCORE has important limitations to
identify high CV risk patients when applied to individuals
under 50 years [3], thus precluding them from the initiation
of statin therapy for primary prevention.This fact constitutes
a major point of concern in AS, a condition associated
with early atherosclerotic disease [4]. In this regard, we
have recently reported that the SCORE underestimates the
actual CV risk of patients with AS [5]. Because of that we
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proposed the use of additional tools, such as the use of carotid
ultrasound (US) to better identify AS at high risk of CV
disease [5, 6].
In an attempt to compensate for the underestimation
of the CV risk in young individuals when the SCORE was
applied, the 2016 ESC guidelines proposed use of a relative
risk (RR) chart score instead of the traditional SCORE system
in individuals younger than 50 years [3]. Unlike the SCORE,
the RR does not define a 10-year absolute risk of a fatal CV
event but indicates the probability of developing a fatal CV
event in an individual with traditional CV risk factors (smok-
ing, hypertension, and hypercholesterolemia) compared to
another individual without them, in whom the RR would be
equal to 1. According to the ESC guidelines, the RR chart
score can help to identify young patients with traditional CV
risk factors who have a low SCORE, promoting in these cases
a stricter preventive CV management [3].
As discussed in the 2016 ESC guidelines, imaging tech-
niques such as carotid US, are useful to improve the CV risk
estimation in the general population and also in patients with
AS [3, 5, 6]. Data from the general population also indicate
that several biomarkers, in particular the C-reactive protein
(CRP), are independent risk factors for CV disease that may
help to improve CV risk stratification [3, 7].
Taking all these considerations together, in the present
study we aimed to determine if the RR chart score may
improve the identification of young AS patients at high risk
of CV disease.
Since an increased frequency of subclinical atherosclero-
sis assessed by carotid US was found in AS without clinically
evident CV disease [4, 8] and a relationship between the CRP
levels at the time of disease diagnosis and the presence of
subclinical atherosclerosis was also disclosed in these patients
[8], we assessed whether both the carotid US and the CRP at
the time of disease diagnosis may improve the sensitivity to
identify high CV risk among young AS patients in whom the
RR charts was applied.
2. Methods
2.1. Patients. A set of 73 consecutive patients between 35 and
50 years seen over a 4-year period at Hospital Universitario
Marqués de Valdecilla and Hospital de Laredo (Cantabria,
Northern Spain) that fulfilled definitions for AS according
to the 1984 modified New York criteria [1] were recruited.
Patients with history of CV events (ischemic heart disease,
cerebrovascular accident, peripheral arterial disease, or heart
failure), diabetes mellitus, and chronic kidney were excluded.
CV risk was estimated according to the total cholesterol-
(TC-) SCORE chart designed for low-risk population such
as the Spanish population and to the RR chart score, both
included in the 2016 ESC guidelines [3]. The TC-SCORE
is calculated considering total cholesterol [3]. Subjects with
SCORE < 1% are included in the category of low risk. Those
with a SCORE ≥ 1% and <5% are in the category of moderate
risk. When the chart SCORE result is ≥5% and <10% they
are classified as having high risk. Finally, those patients with
SCORE results≥ 10% are included in the category of very high
CV risk [3].
The RR for a CV event was also calculated in all these AS
patients considering information related to smoking, systolic
blood pressure, and total cholesterol according to a RR chart
score included in the 2016 ESC guidelines (Figure 1) [3]. The
RR compares the absolute risk of the patient with that of
another patient of the same age and sex, with ideal levels of
risk factors.
CarotidUSwas performed as previously described [9, 10].
Briefly, carotid US examination included the measurement
of carotid intima media thickness (cIMT) in the common
carotid artery and the detection of focal plaques in the
extracranial carotid tree. Plaquewas defined as a focal protru-
sion in the lumen at least cIMT > 1.5mm, protrusion at least
50% greater than the surrounding cIMT, or arterial lumen
encroaching > 0.5mm [9]. The cIMT was determined as
the average of three measurements in each common carotid
artery. The final cIMT was the largest average cIMT (left or
right) [10]. Carotid US was performed using a commercially
available scanner, Mylab 70, Esaote (Genoa, Italy) equipped
with 7–12MHz linear transducer and the automated soft-
ware guided technique radiofrequency-quality intima media
thickness in real-time (QIMT, Esaote, Maastricht, Holland).
Patients with carotid plaques were considered as having very
high CV risk [3, 10].
C-reactive protein (CRP) data at time of the disease
diagnosis were also assessed. As previously described [11],
a value of CRP higher than 3mg/L was considered as a
predictive factor for future CV events.
A subject’s written consent was obtained in all the cases.
The study was approved by the local Ethical Committee.
2.2. Statistical Methods. Categorical variables were described
as percentages and quantitative variables as mean ± standard
deviation (SD) or median (interquartile range [IQR]).
For eachCV riskmodel, sensitivity, specificity, percentage
of correctly classified patients, and area under the Receiver
Operating Characteristic (ROC) curve (with 95% confidence
interval) were estimated. A logistic regressionmodel was per-
formed to estimate the relationship between the CRP higher
than 3mg/L at disease diagnosis and presence of carotid
plaques, adjusting the results for potential confounding
factors (sex, age at study, arterial hypertension, dyslipidemia,
obesity, and smoking).
3. Results
The main features of the 73 AS patients under 50 years are
summarized in Table 1.
Twenty AS patients (27.4%) had carotid plaques. Interest-
ingly aCRPvalue greater than 3mg/L at disease diagnosiswas
associatedwith the presence of carotid plaques after adjusting
for age, sex, obesity, hypertension, dyslipidemia, and smoking
(odds ratio 5.56, 95% confidence interval 1.11–28.77; 𝑝 =
0.03).
3.1. TC-SCORE Risk Calculation. Most young AS patients
(𝑛 = 59, 80.8%) were included in the category of low CV
risk when the TC-SCORE was applied. Only 14 (19.2%) were
found to havemoderate CV risk according to the TC-SCORE
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Figure 1: Relative risk chart, derived from SCORE. Based on the ESC 2016 guidelines [3].
and none of them had a TC-SCORE ≥ 5%, which indicates
high or very high CV risk.
Twelve of the 59 (20.3%) patients categorized as having
low CV risk according to the TC-SCORE risk charts were
found to have carotid plaques. The frequency of subclinical
atherosclerosis was higher in those classified as having
moderate CV risk since 8 (57.1%) of 14 patients withmoderate
CV risk according to the TC-SCORE algorithmwere found to
have carotid plaques.
3.2. Relative Risk and Carotid US Findings in Patients with AS.
Only 5 of the 35 (14.2%) with RR = 1 had carotid plaques.The
frequency of carotid plaques was higher in those with RR > 1
(15 [39.5%] of 38 with RR > 1) (Table 2).
3.3. Predictive Model to Establish the Presence of High or
Very High CV Risk in Young Patients with AS. We set up a
predictive model to identify young AS patients at high CV
risk (Table 3).
Based on 2016 ESC guidelines, we classified patients as
having high/very high CV risk if they had a TC-SCORE ≥ 5
or carotid plaques. Following this approach 20 of 73 patients
fulfilled definitions of high/very high CV risk, all of them due
to the presence of carotid plaques (model 2) since none of the
73 AS patients had a TC-SCORE ≥ 5 (model 1).
A predictive model that included patients with TC-
SCORE ≥ 5% or patients with TC-SCORE ≥ 1% <5% plus
carotid plaques only identified 8 (40%) of the high/very high
CV risk AS patients with a specificity of 88.7% (area under
the curve [AUC]: 0.64) (model 1). In contrast, a carotid US
performed in patients with RR > 1 who had CRP levels
greater than 3mg/L at time of disease diagnosis yielded a
sensitivity and a specificity of 60% and 77.4%, respectively
(AUC: 0.69) (model 2). Interestingly, the sensitivity of the
model was higher (75%) if the carotid US was performed
in young AS patients with RR > 1 regardless of CRP data at
the time of disease diagnosis but the specificity decreased to
56.6% (AUC: 0.66) (model 3) (Table 3).
4. Discussion
This is the first study aimed at evaluating the ability of
a RR chart score to improve the identification of high
risk CV disease among young AS patients. In our study,
the RR demonstrated being superior to the SCORE risk
function to identify high CV risk AS patients under 50 years,
thus allowing them to benefit from an intensive preventive
therapy. This is a crucial aspect considering that statins have
been shown to decrease mortality by 37% in AS, a figure that
doubles that observed in the general population [12].
We also confirmed the limitations attributed to the
SCORE system when applied to AS patients under 50 years
[3]. Although 27% of our patients had severe carotid US
findings, most of them had been classified as having “low
risk” based on the SCORE algorithm.Theuse of RR improved
the identification of high CV risk young AS patients. In this
regard, AS patients with RR > 1 were almost three times more
likely to have subclinical atherosclerosis than those with RR
= 1 (39.5% versus 14.3%).
CRP at disease diagnosis, which probably mirrors the
presence of a prolonged subclinical inflammatory burden
since the diagnosis is often delayed in patients with AS, was
also found to be useful to improve the identification of high
risk CV disease AS patients. In keeping with that, the 2016
ESC guidelines consider CRP as a proatherogenic factor with
a similar influence to that attributed to the traditional CV
risk factors, also capable of improving CV risk estimation
[3]. Several studies indicate the cut-off point at which CRP is
associated with an increased risk of CV events at 3mg/L [11,
13]. In our series, 52,1% of AS patients had CRP levels higher
than 3mg/L at time of disease diagnosis, before receiving
anti-TNF drugs that may reduce their levels, and this value
was significantly associated with the presence of carotid
plaques even after adjustment for confounding factors. The
combination of a RR > 1 plus a CRP level at disease diagnosis
higher than 3mg/L increased the probability of disclosing
severe subclinical disease expressed by the presence of carotid
plaques up to 60%. Using this predictive model, we would
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Table 1: Main epidemiologic, clinical, and ultrasonography features of a series of 73 ankylosing spondylitis patients without cardiovascular
events, diabetes mellitus, or chronic kidney disease between 35 and 50 years.
Variable AS (𝑛 = 73)
Men/women, 𝑛 44/29
Age at the time of study (years), mean ± SD 41.49 ± 3.85
Age at the time of diagnosis (years), mean ± SD 35.84 ± 6.49
Delay to disease diagnosis (years), mean ± SD 7.59 ± 7.90
Disease duration (years), median (IQR)
Since first symptoms 12.00 (7.00–19.50)
Since diagnosis of AS 5.00 (1.00–9.00)
BASDAI, mean ± SD 3.46 ± 2.07
ASDAS, mean ± SD 2.18 ± 0.91
BASFI, mean ± SD 3.31 ± 2.45
BASMI, mean ± SD 2.46 ± 1.30
MASES, median (IQR) 1.00 (0.00–4.00)
Extra-articular manifestations, 𝑛 (%) 21 (28.77)
Psoriasis, 𝑛 (%) 8 (10.96)
Inflammatory bowel disease, 𝑛 (%) 3 (4.11)
Uveitis, 𝑛 (%) 14 (19.18)
History of synovitis or enthesitis, 𝑛 (%) 36 (49.32)






HLA-B27 positive, 𝑛 (%) 55 (75.34)
CRP (mg/l), median (IQR)
At time of study 2.00 (0.50–6.00)
At time of disease diagnosis 4.00 (2.00–10.50)
CRP > 3mg/L at time of disease diagnosis, 𝑛 (%) 38 (52.05)
ESR (mm/1st hour), median (IQR)
At time of study 6.00 (3.00–14.50)
At time of disease diagnosis 10.00 (4.50–17.50)
History of classic cardiovascular risk factors, 𝑛 (%)
Current smokers 22 (30.14)




Blood pressure (mm Hg), mean ± SD
Systolic 127.00 ± 13.84
Diastolic 79.47 ± 9.86
Cholesterol or triglycerides (mg/dl), mean ± SD
Total cholesterol 198.00 ± 33.80
HDL cholesterol 54.57 ± 12.99
LDL cholesterol 122.40 ± 33.32
Triglycerides 87.82 ± 43.11
Carotid plaques, 𝑛 (%) 20 (27.40)
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Table 1: Continued.
Variable AS (𝑛 = 73)
SCORE-TC, 𝑛 (%)
Low (<1%) 59 (80.82%)
Moderate (≥1% and <5%) 14 (19.17%)
High (≥5% and <10%) 0
Very high (≥10%) 0
SD: standard deviation. IQR: interquartile range.
Table 2: Presence of carotid plaques in 73 AS patients between 35 and 50 years without cardiovascular events, diabetes mellitus, or chronic
kidney disease who were categorized according their relative risk (RR) chart score.
RR
Carotid ultrasound
Presence of carotid plaques
𝑛 = 20 (27.4%)
1 𝑛 = 35 (47.9%) 5 (14.3%)
2 𝑛 = 22 (30.1%) 8 (36.4%)
3 𝑛 = 12 (16.4%) 5 (41.7%)
4 𝑛 = 3 (4.1%) 1 (33.3%)
5 𝑛 = 1 (1.4%) 1 (100%)
>1 𝑛 = 38 (52.1%) 15 (39.5%)
Table 3: Study of 73 AS patients between 35 and 50 years without cardiovascular events, diabetes mellitus, or chronic kidney disease.
Sensitivity, specificity, percentage of correctly classified patients, and area under the ROC curve of three different models based on the TC-
SCORE algorithm, the relative risk (RR) chart score, and a value of CRP higher than 3mg/L at time of disease diagnosis along with the
performance of carotid (US) to establish the presence of high/very high cardiovascular risk.
Sensitivity Specificity Correctly classified ROC [95% CI]
Model 1
TC-SCORE ≥ 5% OR
TC-SCORE ≥ 1% <5% plus
carotid Carotid US
(presence of plaques)
40% 88.7% 75.3% 0.64 [0.53–0.76]
Model 2
RR > 1 and CRP > 3 mg/L
at time of disease diagnosis
plus carotid US (presence
of plaques)
60.0% 77.4% 72.6% 0.69 [0.56–0.81]
Model 3
RR > 1 plus carotid US
(presence of plaques)
75.0% 56.6% 61.6% 0.66 [0.53–0.78]
TC-SCORE: total cholesterol systematic coronary risk evaluation, US: ultrasound, RR: relative risk, and CRP: C-reactive protein. The gold standard used to
define high/very high cardiovascular risk was the presence of TC-SCORE ≥ 5% or carotid plaques.
narrow the number of patients to be assessed by carotid US to
only a third of the whole population of young AS.This model
showed a lower sensitivity than that obtained by performing
carotid US to all young AS patients with a RR chart score
> 1. Nevertheless, it exhibited a significantly higher overall
specificity resulting in a higher AUC value (0.69 versus 0.66).
In addition, its feasibility in clinical practicewas also superior.
Identification of high CV disease risk AS patients is
an issue of major relevance to initiate prompt primary
prevention and consequently reduce the potential risk of fatal
CV events in these patients. Statins achieve a reduction in the
number of major vascular events in the lowest risk categories
at least as big as in the higher risk groups, according to a
recent meta-analysis of clinical trials [14]. Another argument
that supports this strategy is the fact that the use of statins in
individuals with CRP higher than 2mg/L has demonstrated
decreasingmortality bymore than 30%, regardless of the lipid
level [15].
In conclusion, our study confirms that AS patients
under 50 years often have subclinical atherosclerotic dis-
ease. Although they are not identified by the use of the
SCORE algorithm, due to the presence of carotid plaques,
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these patients would be considered as having high CV risk.
Nevertheless, RR chart score assessment may help to identify
young AS patients at high risk of CV disease. Most of them
may be identified by combining the use of a RR chart score
along with CRP levels at disease diagnosis and carotid US,
which are tools proposed by the 2016 ESC guidelines experts
to improve CV disease risk stratification.
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